Literature DB >> 28082235

From stable disease to acute-on-chronic liver failure: Circulating cytokines are related to prognosis in different stages of cirrhosis.

Josiane Fischer1, Telma Erotides Silva1, Pedro Eduardo Soares E Silva1, Bruno Silveira Colombo1, Mariana Costa Silva1, Letícia Muraro Wildner2, Maria Luiza Bazzo2, Elayne Cristina Morais Rateke2, Tania Silvia Frode2, Silvana Vigil de Mello2, Júlia S Rosa2, Esther Buzaglo Dantas-Correa1, Janaína Luz Narciso-Schiavon1, Leonardo Lucca Schiavon3.   

Abstract

INTRODUCTION: Although both pro- and anti-inflammatory circulating cytokines are known to be elevated in liver cirrhosis, its clinical significance is not completely recognized. Our aim was to evaluate the prognostic significance of circulating cytokines interleukin (IL)-6, IL-17 and IL-10 in different stages of cirrhosis.
METHODS: This prospective study included two cohorts: (1) stable cirrhosis attended in the Outpatient Clinic (n=118), and (2) subjects hospitalized for acute decompensation (AD) (n=130). Thirty healthy subjects served as control group.
RESULTS: Patients with cirrhosis exhibited higher levels of cytokines as compared to controls. In stable cirrhosis, during a median follow-up of 17months, liver-related events occurred in 26 patients. Higher IL-10 levels and Child-Pugh B/C were independently associated with reduced event-free survival. In AD cohort, death after 90days of follow-up occurred in 39 patients and was independently associated with ascites, higher IL-6 and model for end-stage liver disease. IL-6 levels also showed higher AUROC than CRP for predicting bacterial infection in the AD cohort (0.831±0.043vs. 0.763±0.048, respectively). IL-17 decreased at third day of hospitalization only in patients who progressed to death. Higher IL-6 levels were observed in acute-on-chronic liver failure (ACLF) patients even in the absence of bacterial infection whereas IL-10 was higher only in subjects with infection-related ACLF. Higher IL-10 and IL-17 levels were associated with progression to death in ACLF.
CONCLUSIONS: The pattern of immune response seems to vary according to the phase of cirrhosis and is related to prognosis, from stable disease to ACLF. Copyright Â
© 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytokines; Interleukin-10; Interleukin-17; Interleukin-6; Liver cirrhosis

Mesh:

Substances:

Year:  2017        PMID: 28082235     DOI: 10.1016/j.cyto.2016.12.017

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  14 in total

1.  Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis.

Authors:  Antonio Riva; Elizabeth H Gray; Sarah Azarian; Ane Zamalloa; Mark J W McPhail; Royce P Vincent; Roger Williams; Shilpa Chokshi; Vishal C Patel; Lindsey A Edwards
Journal:  JHEP Rep       Date:  2020-07-30

Review 2.  Roles of hepatic stellate cells in acute liver failure: From the perspective of inflammation and fibrosis.

Authors:  Juan Li; Ying-Ren Zhao; Zhen Tian
Journal:  World J Hepatol       Date:  2019-05-27

3.  Immune Regulatory Mediators in Plasma from Patients With Acute Decompensation Are Associated With 3-Month Mortality.

Authors:  Natalia Becares; Suvi Härmälä; Louise China; Romain A Colas; Alexander A Maini; Kate Bennet; Simon S Skene; Zainib Shabir; Jesmond Dalli; Alastair O'Brien
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-22       Impact factor: 11.382

4.  Cystatin C and interleukin-6 for prognosticating patients with acute decompensation of cirrhosis.

Authors:  Gaurav Padia; Bhawana Mahajan; Ajay Kumar; Ujjwal Sonika; Amol S Dahale; Sanjeev Sachdeva; Ashok Dalal; Roshan George
Journal:  JGH Open       Date:  2021-03-09

Review 5.  Management of Infectious Complications Associated with Acute-on-Chronic Liver Failure.

Authors:  Cornelius Engelmann; Thomas Berg
Journal:  Visc Med       Date:  2018-07-27

6.  Human Amnion-Derived Mesenchymal Stromal Cells in Cirrhotic Patients with Refractory Ascites: A Possible Anti-Inflammatory Therapy for Preventing Spontaneous Bacterial Peritonitis.

Authors:  Mariangela Pampalone; Simona Corrao; Giandomenico Amico; Giampiero Vitale; Rossella Alduino; Pier Giulio Conaldi; Giada Pietrosi
Journal:  Stem Cell Rev Rep       Date:  2021-01-03       Impact factor: 5.739

Review 7.  Abnormal Innate Immunity in Acute-on-Chronic Liver Failure: Immunotargets for Therapeutics.

Authors:  Arshi Khanam; Shyam Kottilil
Journal:  Front Immunol       Date:  2020-10-08       Impact factor: 7.561

8.  Patterns of dendritic cell and monocyte subsets are associated with disease severity and mortality in liver cirrhosis patients.

Authors:  Chandra Chiappin Cardoso; Camila Matiollo; Carolina Hilgert Jacobsen Pereira; Janaina Santana Fonseca; Helder Emmanuel Leite Alves; Otavio Marcos da Silva; Vivian de Souza Menegassi; Claudia Regina Dos Santos; Ana Carolina Rabello de Moraes; Leonardo de Lucca Schiavon; Maria Claudia Santos-Silva
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

9.  Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway.

Authors:  Hao Ruan; Jiaoyan Luan; Shaoyan Gao; Shuangling Li; Qiuyan Jiang; Rui Liu; Qing Liang; Ruiqin Zhang; Fangxia Zhang; Xiaohe Li; Honggang Zhou; Cheng Yang
Journal:  Molecules       Date:  2021-07-26       Impact factor: 4.411

10.  Pre and post-liver transplant outcome of cirrhotic patients with acute on chronic liver failure.

Authors:  Speranta Iacob; Mihaela Ghioca; Irma Eva Csiki; Dana Tomescu; Gabriela Droc; Doina Hrehoret; Vlad Brasoveanu; Corina Pietrareanu; Razvan Iacob; Cristian Gheorghe; Irinel Popescu; Liana Gheorghe
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.